The findings of this report highlight that biosimilars present a very attractive opportunity for Indian pharma companies, going beyond small molecule generics ridden with intense competition and price pressures. Based on analysis of currently approved biologic drugs and global pipeline, in the most optimistic scenario, the report states that that the global biosimilar market will be worth $ 240 Billion and Indian biosimilars market will be worth $ 40 billion by 2030. Growth is driven by increasing market maturity in Europe, more recent forthcoming environment for regulatory approvals in US and high unmet clinical need across RoW markets.
This report brings out the major challenges to combat and secure a sustainable future for Indian-made biosimilars along with key recommendations.